MA38138A1 - Dérivés inédits de quinolone - Google Patents

Dérivés inédits de quinolone

Info

Publication number
MA38138A1
MA38138A1 MA38138A MA38138A MA38138A1 MA 38138 A1 MA38138 A1 MA 38138A1 MA 38138 A MA38138 A MA 38138A MA 38138 A MA38138 A MA 38138A MA 38138 A1 MA38138 A1 MA 38138A1
Authority
MA
Morocco
Prior art keywords
quinolone
new derivatives
preparation
compounds
formula
Prior art date
Application number
MA38138A
Other languages
English (en)
Inventor
Ranjit C Desai
Vrajesh Pandya
Pankaj R Patel
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54148255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38138(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of MA38138A1 publication Critical patent/MA38138A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)

Abstract

La présente invention concerne des composés inédits de formule générale (i), leurs formes tautomères, leurs stéréo-isomères, leurs sels pharmaceutiquement acceptables, des compositions pharmaceutiques en contenant, leurs procédés de préparation, l'utilisation desdits composés en médecine et les intermédiaires impliqués dans leur préparation. [formule à insérer ici]
MA38138A 2012-12-24 2015-05-29 Dérivés inédits de quinolone MA38138A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN3600MU2012 2012-12-24
PCT/IN2013/000796 WO2014102818A1 (fr) 2012-12-24 2013-12-23 Dérivés inédits de quinolone

Publications (1)

Publication Number Publication Date
MA38138A1 true MA38138A1 (fr) 2016-11-30

Family

ID=54148255

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38138A MA38138A1 (fr) 2012-12-24 2015-05-29 Dérivés inédits de quinolone

Country Status (26)

Country Link
US (1) US9394300B2 (fr)
EP (1) EP2935221B1 (fr)
JP (1) JP6026013B2 (fr)
KR (1) KR101733901B1 (fr)
CN (1) CN104903295B (fr)
AP (1) AP2015008502A0 (fr)
AR (1) AR094300A1 (fr)
AU (1) AU2013368843B2 (fr)
BR (1) BR112015014222B1 (fr)
CA (1) CA2894636C (fr)
CL (1) CL2015001802A1 (fr)
EA (1) EA028402B1 (fr)
ES (1) ES2660288T3 (fr)
IL (1) IL239109B (fr)
JO (1) JO3781B1 (fr)
MA (1) MA38138A1 (fr)
MX (1) MX373392B (fr)
MY (1) MY175854A (fr)
NZ (1) NZ708605A (fr)
PH (1) PH12015501452B1 (fr)
SG (1) SG11201504458XA (fr)
TR (1) TR201802305T4 (fr)
TW (1) TWI598339B (fr)
UA (1) UA117122C2 (fr)
WO (1) WO2014102818A1 (fr)
ZA (1) ZA201503814B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016034108A1 (fr) * 2014-09-02 2016-03-10 广东东阳光药业有限公司 Composé de quinoline et ses applications
WO2016045125A1 (fr) * 2014-09-28 2016-03-31 Merck Sharp & Dohme Corp. Inhibiteurs de la prolyl hydroxylase du hif
CL2015003047A1 (es) * 2015-10-15 2016-06-17 Univ Chile Método ex vivo para detectar precozmente injuria renal aguda en pacientes críticos, que comprende la mediciom en una muestra de tres proteinas como biomarcadores, factor de crecimiento fibroblástico 23, klotho y eritropoyetina
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN108069957B (zh) * 2016-11-09 2022-11-04 广东东阳光药业有限公司 脯氨酰羟化酶抑制剂及其用途
CA3062972C (fr) * 2017-05-09 2021-09-14 Kind Pharmaceutical Derives d'indolizine et leur application en medecine
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ， インコーポレイテッド Ｈｂｖ複製阻害剤としての置換ピロリジン化合物
WO2021181360A1 (fr) * 2020-03-13 2021-09-16 Cadila Healthcare Limited Nouveaux sels de composés de quinolone
US20230190731A1 (en) * 2020-03-17 2023-06-22 Zydus Lifesciences Limited Formulation comprising hif prolyl hydroxylase inhibitors
WO2021216530A1 (fr) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Traitement d'infections virales, d'une lésion d'organe et d'états apparentés à l'aide d'un inhibiteur de hif prolyl hydroxylase ou d'un stabilisateur hif-alpha
CN115666539A (zh) * 2020-05-29 2023-01-31 兹杜斯生命科学有限公司 银屑病和皮肤炎性疾病的治疗
EP4157220A1 (fr) * 2020-06-01 2023-04-05 Zydus Lifesciences Limited Traitement de la maladie inflammatoire chronique de l'intestin
WO2022150623A1 (fr) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Composés et composition pour traiter l'anémie
EP4308120A4 (fr) 2021-03-19 2024-11-27 Zydus Lifesciences Limited Traitement de la drépanocytose
WO2022195525A1 (fr) * 2021-03-19 2022-09-22 Zydus Lifesciences Limited Composé de quinolone sous formes solides et ses procédés de préparation
WO2022238745A1 (fr) * 2021-05-14 2022-11-17 Zydus Lifesciences Limited Composition pharmaceutique topique d'inhibiteurs de hif prolyl hydroxylase
EP4347022A1 (fr) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Formulations pédiatriques de citrate ferrique
CN113549011B (zh) * 2021-08-10 2023-05-09 广东东阳光药业有限公司 德度司他的共晶或盐及其制备方法和用途
CN117836275A (zh) * 2021-09-20 2024-04-05 载度思生命科学有限公司 德度司他颗粒及其组合物
EP4539934A1 (fr) * 2022-06-24 2025-04-23 Zydus Lifesciences Limited Traitement de maladies glomérulaires
EP4565233A1 (fr) * 2022-08-01 2025-06-11 Zydus Lifesciences Limited Traitement de l'anémie aplasique (aa)
WO2025087207A1 (fr) 2023-10-24 2025-05-01 杭州安道药业有限公司 Produit pharmaceutique oral à action prolongée comprenant un inhibiteur de la prolyl hydroxylase du facteur inductible par l'hypoxie et son utilisation

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
WO2004108681A1 (fr) 2003-06-06 2004-12-16 Fibrogen, Inc. Composes heteroaryliques contenant de l'azote et leur utilisation dans l'augmentation de l'erythropoietine endogene
US8703795B2 (en) * 2005-03-02 2014-04-22 Fibrogen, Inc. Thienopyridine compounds, and methods of use thereof
WO2007038571A2 (fr) 2005-09-26 2007-04-05 Smithkline Beecham Corporation Antagonistes de la prolyl-hydroxylase
EP1960363B1 (fr) * 2005-12-09 2014-01-22 Amgen, Inc. Composes a base de quinolone presentant une activite inhibitrice de prolyle hydroxylase, et leurs compositions et utilisations
AR059733A1 (es) * 2006-03-07 2008-04-23 Smithkline Beecham Corp Compuesto derivado de glicina n- sustituida con heteroaromaticos bicicicos, composicion farmaceutica que lo comprende, uso para preparar un medicamento para tratar la anemia y proceso para su preparacion
BRPI0710527B8 (pt) * 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
US20090176825A1 (en) * 2006-05-16 2009-07-09 Fitch Duke M Prolyl hydroxylase inhibitors
US20100056516A1 (en) * 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
ES2393326T3 (es) * 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
US8048894B2 (en) * 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
JP2010524935A (ja) * 2007-04-18 2010-07-22 メルク・シャープ・エンド・ドーム・コーポレイション 新規１，８−ナフチリジン化合物
EP2155746A2 (fr) * 2007-05-04 2010-02-24 Amgen, Inc Diazaquinolones inhibant l'activité de la prolyl hydroxylase
US8030346B2 (en) * 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
AU2008251031B2 (en) * 2007-05-16 2013-12-19 Norman Terry Cowper System and method for maximising solids concentration of slurry pumped through a pipeline
JP2011505367A (ja) * 2007-11-30 2011-02-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー プロリルヒドロキシラーゼ阻害剤
AU2009217541A1 (en) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydrothieno pyridines
CA2716798A1 (fr) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydrofuropyridones
CA2714111A1 (fr) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Pyridones a tetrahydro-1h-pyrrolo fusionne
US20110098324A1 (en) * 2008-06-25 2011-04-28 Brackley Iii James A Prolyl hydroxylase inhibitors
EP3594213A1 (fr) 2009-07-17 2020-01-15 Japan Tobacco Inc. Composés de triazolopyridine et leur action en tant qu'inhibiteurs de prolyle hydroxylase et inducteurs de production d'érythropoïétine
US20120196853A1 (en) * 2009-08-20 2012-08-02 Vifor (International) Ag Novel Quinoline-Hepcidine Antagonists
WO2012106472A1 (fr) 2011-02-02 2012-08-09 Fibrogen, Inc. Dérivés de naphthyridine en tant qu'inhibiteurs d'un facteur inductible par l'hypoxie
EP2758058B1 (fr) 2011-09-23 2017-04-26 Merck Sharp & Dohme Corp. Pyrimidines substituées
CA2863279A1 (fr) * 2012-01-31 2013-08-08 Toyama Chemical Co., Ltd. Compose heterocyclique ayant une activite anti-vih

Also Published As

Publication number Publication date
TR201802305T4 (tr) 2018-03-21
ZA201503814B (en) 2016-05-25
CN104903295B (zh) 2017-09-01
UA117122C2 (uk) 2018-06-25
CA2894636C (fr) 2018-04-03
AP2015008502A0 (en) 2015-06-30
EP2935221A1 (fr) 2015-10-28
JP6026013B2 (ja) 2016-11-16
WO2014102818A1 (fr) 2014-07-03
MY175854A (en) 2020-07-14
AR094300A1 (es) 2015-07-22
BR112015014222A2 (pt) 2017-07-11
MX2015008233A (es) 2015-09-29
CN104903295A (zh) 2015-09-09
TW201441196A (zh) 2014-11-01
ES2660288T3 (es) 2018-03-21
EA201591195A1 (ru) 2015-10-30
JP2016503052A (ja) 2016-02-01
JO3781B1 (ar) 2021-01-31
PH12015501452B1 (en) 2018-06-06
US9394300B2 (en) 2016-07-19
BR112015014222B1 (pt) 2022-12-06
CL2015001802A1 (es) 2015-10-02
SG11201504458XA (en) 2015-07-30
CA2894636A1 (fr) 2014-07-03
IL239109A0 (en) 2015-07-30
HK1211022A1 (en) 2016-05-13
MX373392B (es) 2020-04-20
PH12015501452A1 (en) 2015-09-21
AU2013368843B2 (en) 2016-02-25
KR101733901B1 (ko) 2017-05-08
KR20150085535A (ko) 2015-07-23
TWI598339B (zh) 2017-09-11
US20150299193A1 (en) 2015-10-22
NZ708605A (en) 2016-07-29
AU2013368843A1 (en) 2015-06-18
EP2935221B1 (fr) 2018-02-07
IL239109B (en) 2019-07-31
EA028402B1 (ru) 2017-11-30

Similar Documents

Publication Publication Date Title
MA38138A1 (fr) Dérivés inédits de quinolone
MA38999A1 (fr) Nouveaux composés hétérocycliques
MA37405A1 (fr) Composés hétérocyclyle
MA54653B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
MA42230B1 (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
TN2016000188A1 (fr) Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs.
MA38175B1 (fr) Lactames fusionnés à un aryle et hétéroaryle
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA35826B1 (fr) Triazolopyridines substituées et leur utilisation à titre d'inhibiteurs de ttk
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA37142A3 (fr) Dérivés de dihydro-benzo-oxazine et de dihydro-pyrido-oxazine
MA38287B1 (fr) Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
MA55046B1 (fr) Utilisation de dérivés d'indole n-substitués comme modulateurs des récepteurs des pge2
TNSN08139A1 (fr) Composes therapeutiques
MA37886A1 (fr) Nouvelles pyridinones bicycliques
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA34760B1 (fr) Composés et leurs utilisation
MA38854B1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
MA38679B1 (fr) Modulateurs du récepteur de cxcr7
MA39229A1 (fr) Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines